Bionano Genomics highlights 13 studies proving optical genome mapping's value in reproductive and prenatal health research.

Bionano Genomics announced that in 2026, 13 independent studies involving 730 samples demonstrated the effectiveness of optical genome mapping (OGM) in detecting structural genetic variants related to reproductive health and prenatal disorders. These studies showed OGM's superiority or complementarity to traditional genetic testing methods in identifying causes of infertility, recurrent pregnancy loss, and prenatal genetic conditions. Key findings include OGM detecting previously missed genetic causes in infertility and miscarriage cases, and performing well even with limited prenatal samples. This reinforces OGM's potential to improve genetic diagnosis and counseling in reproductive medicine globally.